The gag proteins of human immunodeficiency virus type 1: mechanisms of virus assembly and possibilities for interference by Modrow, Susanne et al.
Med Microbiol Immunol (1994) 183:177-194 
Mini review 
  and 
9 Springer-Verlag 199,~ 
The gag proteins of human immunodeficiency 
virus type 1: mechanisms of virus assembly and 
possibilities for interference 
Susanne Modrow 1, Bernhard Kattenbeck 1, Andreas von Poblotzki 1, 
Matthias Niedrig 2, Ralf Wagner 1, Hans Wolf 1 
i Institut for Medizinische Mikrobiologie und Hygiene der Universit~it Regensburg, 
D-93042 Regensburg, Germany 
2 Robert-Koch-Institut, Bundesgesundheitsamt, Nordufer 40, D- 13351 Berlin, Germany 
Received: 21 June 1994 
Introduction 
During the last years highly developed methods in molecular biology have allowed 
the accumulation of detailed knowledge concerning the early steps in the course 
of viral infection of individual cells. This has led to the characterization f many 
cellular surface proteins and additional factors involved in the adsorption process 
of individual viruses of specific cells, e.g., for members of the retrovirus group 
(human immunodeficiency virus, HIV), herpes viruses (Epstein-B arr virus, herpes 
simplex virus), picornaviruses (poliovirus, rhinovirus, coxsackievirus), ortho- 
myxoviruses (influenza virus) and many others. In addition to the process of virus 
adsorption to the surface of individual cells, much is known today about cellular 
factors and transactive proteins necessary for the primary steps of virus gene ac- 
tivation and transcription as well as about he regulated processes of gene expres- 
sion and genome replication. In contrast to these early steps during virus infection 
and replication, only very few details are known about he late events of the virus 
life cycle, which lead to the release of infectious virus particles from the infected 
cell. One precondition for the production of these particles is the correct assembly 
of the individual components forming the virion structure represented by the vi- 
rus capsid or core associated with the viral genome and - in the case of enveloped 
virus particles - the lipid bilayer of the host cell associated with viral membrane 
and matrix proteins. The virus structure often becomes further modified by matu- 
ration processes taking place after the diverse components have been assembled 
and released as premature virus particles from the infected cell, thereby finally 
yielding the infective virus. As with the other events occurring during the replica- 
tion cycle, complex mechanisms are involved in the control and performance of 
this viral assembly. 
After the characterization f HIV as the causative agent of the acquired immu- 
nodeficiency syndrome (AIDS) [1, 2] major efforts of research focused on this vi- 
rus in order to understand its molecular biology as a basis for the development of
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new types of vaccines and antiviral therapies. To date this final goal has not been 
achieved; however, these investigations have provided adetailed knowledge of the 
molecular processes occurring during HIV infection. Today we know many details 
about the late steps in the HIV-1 life cycle, i.e., virus assembly and particle mor- 
phogenesis. This knowledge may form a basis enabling us to develop new antivi- 
ral strategies, both through vaccine design and in anti-HIV therapeutics. 
Formation of infectious HIV particles: a multistep procedure 
The assembly process of HIV is similar to that of other members of the lentivirus 
group and to that of C-type and all other retroviruses which are released from the 
membrane of the infected cell in the form of budding particles. Many of the indi- 
vidual events of this complex multistep rocess are not yet finally understood. The 
majority of the structural elements known to be required for HIV-particle forma- 
tion are localized in the sequence of the precursor protein Pr55gag [3] which com- 
prises the matrix protein p 17, the capsid protein p24, the nucleocapsid protein p7, 
the protein p6 known as the link-protein and two smaller peptides p2 and pl [4- 
6], present in infectious virions (Fig. 1). In the course of translation of the viral 
RNA transcripts, these proteins are synthesized in form of a polyprotein precursor 
(molecular mass 55 000 Da), which is cotranslationally modified by addition of 
myristic acid at the penultimate amino-terminal g ycine residue of the Pr55gag; 
the preceeding methione is removed simultaneously [5,7]. This myristic acid mod- 
ification, as well as distinct regions of the Pr55gag itself and cellular components 
involved in these processes, enable the transport and incorporation of this mole- 
cule into the inner leaflet of the cell membrane [8, 9]. In addition to the cellular 
proteins used for myristoylation a d transport of the precursor protein to the mem- 
brane, cyclophilin, a member of cellular enzymes catalyzing protein folding, has 
been proposed to be necessary for group-specific antigen (gag)-protein synthesis, 
transport and membrane targeting [10]. 
A further gag polyprotein representing about 5% of the amount of Pr55gag-pre- 
cursor proteins is synthesized from the same open reading frame, starting with 
identical sequences until a ribosomal frameshift o f -1  occurs in a polyU-rich re- 
gion in the unspliced mRNA in the 3"-region of the gag open reading frame. This 
event leads the translation to proceed past the normal stop codon using another 
reading frame, resulting in a polyprotein precursor Prl60gag-pol (Figs. 1, 2) [11, 
12]. This larger polyprotein comprises the amino acids of Pr55gag up to residue 
432 in the nuclear capsid protein part p7, which are fused to the sequences synthe- 
sized from the "poP' gene of the HIV genome (pol = open reading frame encoding 
virus protease, reverse transcriptase and integrase). Using this ribosomal frame- 
shift the viral protease, reverse transcriptase and integrase are produced as parts 
of the resulting polyprotein precursor Pr160gag-pol. This is also myristoylated and 
targeted to the cytoplasmic membrane by procedures identical to those used for 
membrane incorporation of Pr55gag [8, 9]. 
Besides these two variants of gag-protein precursors, Pr55gag and Prl60gag- 
pol, the viral envelope protein is synthesized by translation of the spliced form of 
viral mRNA into the endoplasmic reticulum (ER). As in cases of other transmem- 
brane proteins, a signal peptide at the amino-terminal end of the gpl60 precursor 
protein associates with the cellular signal recognition particle. The resulting com- 
plex is transported to the ER membrane and the viral glycoprotein is further syn- 
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Fig. 1 A, B. Schematic overview of the HIV- 1 genome and the proteins encoded by the diverse 
genome parts. A Schematic presentation f the HIV- 1 genome and the regions coding for the di- 
verse enzymatic, regulatory active and structural proteins. B Enlargement of the region coding 
for the Pr55gag polyprotein precursor. The regions essential for virus assembly and particle for- 
mation as mentioned in the text (airl, air2, air3) and also the cleavage sites of the HIV-specif- 
ic protease and the resulting protein parts are indicated. The site where the protein sequences en- 
coded by the pol-open reading frame is fused to the Pr55gag protein due to ribosomal frame- 
shifting is indicated 
thesized as descr ibed for t ransmembrane proteins type 1 [13]. In passing the Golgi  
apparatus, everal amino acids of gp 160 are modif ied by glycosylat ion and the pro- 
tein is transported and incorporated into the cel lular membrane [14, 15]. During 
this process the gp l60  precursor protein is endoproteolyt ical ly  c leaved by a cel lu- 
lar furin protease into the external glycoprotein gp l20  necessary for interaction 
with CD4-receptor proteins at the surface of  T helper cel ls and into the transmem- 
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brane protein gp41 [7, 16-18]. Both proteins remain associated by a noncovalent 
linkage. 
By these two processes - targeting the myristoylated forms of Pr55gag and 
Prl60gag-pol via a cytoplasmic pathway to the plasma membrane and use of the 
general transport pathway for transmembrane and secretory proteins for targeting 
of the HIV transmembrane components gpl20/gp41 - all structural and enzymat- 
ically active components ofthe virus become associated with the cytoplasmic mem- 
brane of the cell (Fig. 2 A). During the following steps of HIV assembly two events 
have to occur: first, the viral mRNA genome must interact via its r which is 
located upstream of the start of the open reading frame coding for the gag protein 
and is present only in complete and unspliced messengers, with the RNA-binding 
domain in the nucleocapsid protein portion of the Pr55gag polyprotein [19]. This 
region shows similarities to nucleic acid binding zink-finger motifs [20-23]. Sec- 
ond, the individual protein molecules - Pr55gag, Prl60gag-pol, and gpl20/gp41 
- interact to form clusters with high concentrations of the indicated proteins at the 
lipid bilayer [24, 25]. They can be identified electron microscopically as electron- 
dense regions underneath t e cytoplasmic membrane [4, 26, 27]. These regions 
represent the initial budding structures. Membrane protrusions develop, which pro- 
ceed to form rounded, spherical membraneous particles containing two copies each 
of the HIV-RNA genome (Fig. 2 B, C). These structures are finally released from 
the surface of the cell and represent non-infective, premature viral particles. The 
role of the accessory proteins vpr, vpu and vif in these late steps of the budding 
process remains to be elucidated [28-31]. 
The majority of the maturation steps occur after the premature HIV particles 
have been released, whereby an important role is performed by the viral protease. 
The sequence of this enzyme is localized in the Prl60gag-pol-precursor protein 
immediately downstream of the frameshift site, i.e., the protease sequences are di- 
rectly fused to the gag protein region. The HIV protease is a member of aspartate 
proteases and has to dimerize to yield an active enzyme [32-34]. Furthermore, the 
enzymatic activity of the protease is dependent on an acidic milieu, present only 
inside the released particles [35]. These two preconditions for HIV protease activ- 
ity - dimerization and an acidic environment - prevent proteolytic leavage of 
cellular proteins. Nevertheless, there are some recent indications that a partial intra- 
cellular activation of the protease may contribute to the cytotoxic effects of the vi- 
rus (vonder Helm, unpublished observation and [36]). Optimal enzyme activity 
is, however, only present in the released particles, where the high density of Pr55gag 
and Prl60gag-pol proteins promote dimerization of the protease moieties in the 
precursor molecules and the enzyme is excised by autocatalytical ctivation 
[37]. By the endoproteolytic activity of the HIV protease the Pr55gag- and 
Prl60gag-pol-precursor molecules are cleaved into the proteins identified in in- 
fectious viral particles as pl7MA, p24CA, p7NC, p6Li and the previously men- 
tioned viral enzymes [6, 7, 38, 39]. The matrix protein pl7MA remains associated 
with the viral membrane mainly by the myristic acid modification, p24CA is ar- 
ranged in a way to give the conical core structure found only in mature HIV par- 
ticles [40]; p7NC is complexed by the zink-finger domain with the RNA genomes 
and p6LI seems to form the core-envelope link, facilitating the closure of the spher- 
ical core (Fig. 2D) [30, 41, 42]. Since all these steps during the assembly process 
are highly critical for the formation of infectious HIV particles, each one may 
be individually targeted to disturb and destroy the infectivity of the virus. There- 
fore, much work has been done to define the molecular details of the individual 
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HIV-assembly and maturation 
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Fig. 2A-D. Presentation f the individual steps during HIV-assembly and particle formation A 
Pr55gag and Prl60gag-pol precursor proteins are translated from genomic mRNA in the cyto- 
plasma of the cell, myristoylated, transported to and incorporated into the cell membrane. Spliced 
forms of mRNA encoding the sequences for the envelope proteins are translated into the endo- 
plasmic reticulum (ER), modified by glycosylation and transported via the Golgi apparatus to 
the cell membrane. During this process the precursor protein gp 160 is processed into gp 120 and 
gp41 by the cellular protease furin. B The membrane associated Pr55gag and Pr 160gag-pol poly- 
protein precursor interact to form a submembraneous layer of high density of these proteins; the 
complexes of the envelope proteins become incorporated into these patches containing high con- 
centrations of gag-proteins. C The membrane r gions containing high concentrations of viral 
structural proteins begin to form protrusions representing the initial budding structures. During 
this process two genomic RNA molecules become associated via their tp sequences with the zink- 
finger domains located within the p7NC protein part of the Pr55gag polyprotein precursor. The 
budding complex further ounds up to form a spherical particle still associated with the surface 
of the cell D The immature HIV particle is finally released from the cell surface. Due to the high 
concentration f structural proteins the protease domains dimerize as parts of the Prl60gag-pol 
polyprotein precursor molecules thus forming the active protease which is cleaved from the pre- 
cursor by autocatalytical activation. The active protease further processes the Pr55gag- and 
Pr55gag-pol-precursor pr teins into plTMA, p24CA, p7NC, p6LI and the reverse transcriptase 
and integrase, respectively. The resulting particle undergoes structural changes forming the con- 
ical core structure typical for mature infectious HIV particles 
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steps and to use them as a basis for the development of rational antiviral strate- 
gies. 
Viral proteins and amino acid sequences involved in morphogenesis 
All functions necessary and sufficient for HIV morphogenesis and particle release 
are localized in the sequence of the Pr55gag-precursor protein. This has been dem- 
onstrated by the fact that this protein is able to induce the formation of virus-like 
particles (VLPs) in the absence of further viral structural components like 
Prl60gag-pol and gpl20/gp41 proteins as well as regulatory polypeptides. When 
Pr55gag is transiently [43-45] or stably expressed in eucaryotic cells, or after in- 
fection of cells with recombinant vaccinia virus [46-48]  or baculoviruses [3, 49, 
50], it promotes the formation and release of VLPs from the respective cells, which 
morphologically resemble noninfectious immature HIV particles. This noninfec- 
tious system allows the detailed analysis of regions within the Pr55gag proteins 
important for the formation of particulate structures. 
Using these approaches large regions, particularly in the matrix protein p17, 
were identified to be essential for correct particle assembly. When residues 16 
to 99 were deleted, the release of HIV particles from cells was reduced up to ten- 
fold, budding events occurred preferentially at the membrane of the ER and 
incorporation of gpl60 into the particulate structures was inhibited [24, 51]. 
Similar observations which defined regions of pl7MA to be essential for glyco- 
protein incorporation were found by Yu and coworkers [25]. Furthermore, amino- 
terminal mutations were demonstrated to block intracellular transport of the 
gag-precursor protein [9]. The fact that regions spanning the cleavage site be- 
tween pl7MA and p24CA are also essential for the production of virus-like gag 
particles was shown using recombinant vaccinia viruses expressing altered gag 
proteins in which residues 99-154 (assembly important region 3, air3) were 
deleted [52]. In addition distinct other deletions within the p24CA (amino acids 
211-241) and the p6LI domain (436-471) of Pr55gag protein were without 
influence on the production of virus-like gag particles (Fig. 1). Furthermore, in
terms of future vaccine development the latter two region could easily be substi- 
tuted by peptide sequences from HIV envelope- and nef proteins to allow presen- 
tations of immunogenic epitopes by chimeric VLPs to the immune system [50, 52, 
531. 
More defined alterations in the sequence of the Pr55gag polyprotein exerting 
an influence on the production of virus-like gag particles were identified by von 
Poblotzki et al. [54] using recombinant vaccinia viruses with a deletion of 12 amino 
acids (341 -352) in the p24CA protein (air2). In addition to this deletion, mutants 
were created by site-directed mutagenesis in this region by altering three consec- 
utive amino acids to alanines (Table 1). According to these experiments, the func- 
tionally active residues localized in this domain could be defined as ATLEEM 
(341-346) and CQG (350-352). This domain is of special interest since these 
amino acid sequences are highly conserved between the members of the family of 
mammalian immunodeficiency viruses. In different ypes of retroviruses, for ex- 
ample in Rous sarcoma virus (RSV), the carboxy-terminal domain of the capsid 
protein is important during the assembly process [55]. It is supposed to be involved 
in protein-protein teractions between individual gag-precursor molecules. It is 
noteworthy to mention that synthetic peptides panning residues 339-350 inhibit 
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the release of infectious HIV when added to cell cultures infected with the virus 
[56]. This aspect will be described in detail below. 
When Pr55gag polyproteins containing the above-mentioned mutations were 
expressed by recombinant baculoviruses a significant reduction in the release of 
virus-like particles in comparison to wild-type HIV gag protein could be shown 
(Table 1). In contrast to the system of recombinant vaccinia viruses, certain num- 
bers of particulate structures are still formed and released from the cell, probably 
due to the extremely high expression of Pr55gag under control of the baculovirus- 
specific potyhedrin promotor. Besides their reduction in number some mutant par- 
ticles show a different, slightly higher, density in sucrose gradients when compared 
to the wild-type gag protein. 
Similar effects were also shown when amino acids 47-59  in the pl7 matrix 
protein (airl) were exchanged in tripletts to alanine residues. Expression of these 
constructs in recombinant baculoviruses likewise led to a reduced particle release, 
with partly altered ensities (Table 1). In particular the region between amino ac- 
ids 55 and 60 (EGCRQ) seems to be involved in the viral assembly process, since 
mutations at this site resulted in a strong inhibitory impact on particle release (Kat- 
tenbeck et al., unpublished ata). In accord, proviral constructs with mutations in 
this region were recently shown to be replication defective [24, 25]. This result is 
of special importance since synthetic peptides derived from this domain could also 
be shown to inhibit the production of infectious HIV [56]. 
Possibilities to inhibit particle formation 
Inhibitors of the viral protease 
As described above the endoproteolytic a tivity of the HIV-encoded protease is 
highly important for the process of virus maturation. When this enzyme becomes 
inactivated or is inhibited by certain drugs, the Pr55gag- and Prl60gag-pol-pre- 
cursor proteins are not processed and the viral enzymes necessary for reverse tran- 
scription and integration of the viral genome in newly infected cells are not acti- 
vated. The elucidation of the molecular structure of the HIV protease by X-ray 
crystallography [32] and molecular dynamic simulation [57] facilitated the devel- 
opment of improved compounds able to inhibit its proteolytic activity and, there- 
fore, the succeeding maturation events. HIV-infected cells treated with inhibitors 
of the viral protease do not lead to the production of infectious viral particles [58, 
59]. The particulate structures still budding from the cell surface represent imma- 
ture, spherical HIV particles lacking the ability to form the conical capsid-core 
structure characteristic for infectious virions. Therefore, many investigations fo- 
cused on the development of therapeutically active inhibitors of the HIV protease 
which may be used to suppress virus replication in HIV-infected individuals and 
limit the virus load in these persons. In addition to some approaches todisturb dim- 
erization of the protease [60] or block its active site with various chemicals, syn- 
thetic peptides representing potential cleavage sites were used to inhibit the activ- 
ity of the enzyme. This approach resulted in the development of R31-8959, one 
example of specific inhibitors of HIV protease, which has been administered to 
humans alone or in combination with inhibitors of reverse transcriptase [61, 62]. 
A general problem arising from inhibition of viral enzyme activity is the ten- 
dency of HIV to high mutability and the generation of drug-resistent virus strains. 
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These mutated HIV variants can be easily isolated from HIV patients treated for 
therapeutic reasons with inhibitors either specific for v.irus protease or reverse tran- 
scriptase [63]. Therefore, it may prove to be more successful to disturb other non- 
enzymatic steps, like HIV-particle production, which do not suffer from mutational 
escape vents. These functions may be highly conserved since they occur similarly 
in all budding lentiviruses, can be correlated with distinct protein domains and re- 
quire a similar set of cellular and viral components. 
Compounds interfering with virus assembly 
When overlapping synthetic peptides - 22 -24  amino acids in length -, which to- 
gether epresent the entire sequence of Pr55gag [64], were tested for their respec- 
tive capacity to influence the assembly process of viral gag proteins by defining 
their ability to inhibit the release of infectious virus particles, four peptides were 
found which significantly reduced the amount of infectious HIV produced in the 
peptide-treated cell cultures. Two peptides represent overlapping compounds in 
the central part of p17, the other two peptides comprised sequences of the p24 cap- 
sid protein (Fig. 3, Table 2). The amount of released progeny virus was quantified 
indirectly by determining the activity of the HIV-specific reverse transcriptase in 
cell culture supernatants, hence reflecting the concentration of infectious virus in 
biological samples [65]. The level of infectious HIV was reduced about 100-fold 
in cultures treated with the reactive peptides in comparison to the non-treated HIV- 
infected sample. The peptide effects were dose dependant in a range from 40 to 
200 ~tg/ml. Amounts of 25 tag/ml and below were not active. Furthermore, the ef- 
fect could not be overcome by infecting cell cultures with an unnaturally high HIV 
concentration of up to 400 TCIDs0. Similar effects could be observed on HIV re- 
lease from chronically infected H9 cells and on acutely HIV-infected Jurkat cells. 
In the latter case, peptides were added to the cell cultures after virus adsorption. 
In both systems a similar reduction of infectious HIV particles released from the 
cells into the supernatant was found. When used in the indicated amounts, the pep- 
tides did not show toxic effects on the cells [56, 66]. By use of shortened peptides 
spanning the overlapping parts of the active regions, we were able to define resi- 
dues 47-59  (airl, NPGLLETSEGCRQ) in pl7MA and 339-349 (air2, PAAT- 
LEEMMTA) in p24CA as active parts. To further characterize the functionally ac- 
tive amino acids, peptide derivatives in which tripletts of consecutive amino acids 
were substituted for alanine were synthesized and tested [56]. This allowed fur- 
ther delineation of the active regions to residues 50-58  (LLETSEGCR) in air1 
and 342-349 (TLEEMMTA) in air2. 
When peptide-treated cells were analyzed in the electron microscope, particu- 
late structures were found to be released from the cell surface which did not con- 
tain the conical core structure typical for mature lentivirus particles (Fig. 4). For 
this reason the vesicles were rather similar to immature virus particles. These ob- 
servations indicated that the peptides exerted their activities by influencing arather 
late step during HIV replication, namely virus assembly, since the early regulatory 
functions necessary for the synthesis of structural proteins were obviously not af- 
fected. Furthermore the ability of the peptide-treated cells to form syncytia in the 
cell cultures howed that the synthesis and incorporation of gpl20/gp41 into the 
cell membrane was not negatively influenced. To test what amounts of the pep- 
tides might be cell associated and what proportion of the added molecules may 
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Inhibition of HIV production 
by gag peptides 
RT act iv i ty  [cpm] 
5000 
500 
~-~'~_~ 40 ug/ml 
VK 100 TCID50 
1 5 10 15 20 25 30 35 40 VC 
number of peptides 
Fig. 3. Influence of the 41 Pr55gag protein-derived peptides on the release of infectious HIV 
particles from infected Jurkat cells. Cells were treated with 40 tag/ml peptide after HIV adsorp- 
tion. After 3 days the supernatants were analyzed for the presence and the amount of infectious 
HIV using aliquots of 100 ~tl to infect fresh Jurkat cells which were incubated for 2 weeks. The 
amount of HIV in the supernatants of these indicator cells was determined by quantification f
reverse transcriptase activity. VC Positive control; HIV-infected Jurkat cells without peptides, 
the negative control is given by the value of reverse transcriptase activity in the supernatants of 
uninfected cells 
pass the lipid bilayer, tyrosinylated forms of the shortened variants of the active 
compounds were synthesized and labelled with 125I. The radioactively labelled 
peptides were incubated in various concentrations with uninfected Jurkat cells. In 
the case of the peptide derived from airl, 21% remained cell associated after sev- 
eral washing procedures. For the air2 peptide an amount of 6.5% was shown to be 
irremoveable (Table 3). The percentage of radioactivity associated with the cell 
was not altered to any major extent using either different amounts of labelled pep- 
tides in concentrations below saturation or by altering the incubation time from 2 
to 4 h. These observations indicated that defined quantities of the peptides are, at 
least, cell associated, i.e., taken up by the cell. Therefore, we postulate that the 
peptides pass the cellular membrane by still unknown mechanisms. Peptide trans- 
porters have been described to be present in the membrane of the ER. They were 
shown to translocate proteolytically degraded peptides into this compartment 
where they associated with major histocompatibility complex (MHC) class I pro- 
teins. Recently, peptide-transporter complexes also have been found in the mem- 
branes of rabbit small intestine and various other cells [67]. It may be assumed that 
similar proteins, which actively transport organic compounds, are involved in the 
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Fig. 4. A Electron microscopic presentation of the particulate structures released from peptide 
air2-treated HIV-l-infected H9 cells; only spherical particles with characteristics of immature 
HIV are released from the cell surface. Bar represent 1 ~m. B Magnification of immature parti- 
cles budding from HIV-infected peptide-treated H9 cells. C Positive control of HIV-infected, 
non-peptide-treated c lls: Mature HIV particles with conical capsid structures are released from 
H9-cells. Bar represents 100 nm 
import of  the peptides into the cytoplasm of the cell where they may exert their re- 
spective functions. 
The particulate structures released from peptide-treated cells were similar to 
immature particles produced in HIV-infected cell cultures treated with inhibitors 
specific for the HIV protease [58], or when the sequences encoding the protease 
were mutated [68]. This morphological similarity implied that the active peptides 
could represent unnatural substrates exerting their inhibitory activity in a compet- 
itive way to the cleavage sites in the Pr55gag- and Prl60gag-pol-precursor pro- 
teins. To test this possibility, the peptides were tested in an in vitro system for their 
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Table 3. Amino acid sequences active in form of synthetic peptides to inhibit the release of in- 
fectious HIV from cell cultures. 
Peptide/amino acid sequence Protease Cellular 
inhibition uptake 
IC 50 (pg/ml) % 
air 1 
4: WAS RELERFANGPLLETSEGCRQIL 59.0 
5: NPGLLETSEGCRQILGQLQPSLQT 530.0 
NPGLLETSEGCRQIL 18.5 21 
air2 
28: ANPDC KTILKALGPAATLEEMMTAC >666.0 
29: AATLEEMMTACQGVGGPGHKARVLA 240.0 
AATLEEMMTAC >666.0 6.5 
The respective influence of the peptides on protease activity and the percentage of iodinated 
peptides that remain associated with the cells after incubation periods are indicated 
respective activities to inhibit the HIV-1-specific protease. The majority of the der- 
ivates had no inhibitory influence on this enzyme and particularly the shortened 
forms of the active peptides did not show any activity at all (Table 3). Therefore, 
the inhibitory effect on particle release appeared not to be due to an effect on pro- 
tease activity. 
Besides viral protease, other viral or cellular functions might also be the target 
for the peptides. One of the cellular processes involved might be at the level of en- 
zymes catalyzing protein folding. It was reported [10] that cyclophilin, represent- 
ing a member of the family of cellular chaperones, binds to the gag-precursor p o- 
teins and might influence the correct assembly of HIV components. The regions 
of Pr55gag proposed to be involved in the binding of cyclophilin do not correlate 
with the domains'air1 and air2 from which the active peptides were derived. Nev- 
ertheless, we can not exclude that the peptides might bind to cyclophilin and in- 
fluence its catalytic function. For this reason we analyzed the peptides for their re- 
spective capacity to bind or inhibit the function of cyclophilin. However, none of 
the peptides active in the inhibition of release of infectious HIV bound or influ- 
enced the activity of cyclophilin. Hence, we conclude that this cellular enzyme - 
like the viral protease - is not a target for the peptides. 
At the moment he exact mechanism of activity of the peptides remains unre- 
solved. Various cellular systems involved in modification and transport of the 
Pr55gag-precursor protein may be involved including further cellular chaperones, 
since so far only the interaction with cyclophilin A and B has been tested. It also 
remains possible that the peptides may exert heir inhibitory activity on the release 
of infectious particles by direct interaction with the Pr55gag-precursor proteins in- 
corporated in the cytoplasmic membrane, thus reducing the concentration of these 
polypeptides. Incorrect budding, in combination with incomplete interaction of in- 
dividual gag molecules, and consequent activation of the HIV-specific protease, 
may lead to the formation of immature noninfectious particles. It is important to 
note that the inhibitory effect can not be washed out by diluting the immature par- 
ticles in fresh medium or buffers. Even then the particulate structures remain non- 
infectious. This observation is in contrast to the activities of inhibitors of viral en- 
zymes such as protease or reverse transcriptase. 
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The fact that both synthetic peptides derived from Pr55gag-protein sequences 
influence virus morphogenesis and the identical original amino acid regions are 
important for particle formation led us to the conclusion that intrinsic and defined 
functions of the gag protein are affected [24, 25, 54]. When certain peptides were 
added to HIV-infected cell cultures, the overall formation of virus particles was 
reduced and the shape of the released particles was altered. If functionally impor- 
tant residues of these active synthetic peptide derivatives were deleted or ex- 
changed, their inhibitory action on particle release ceased. When residues of the 
same region in the Pr55gag sequence were exchanged in gag protein expression 
systems, the production of HIV-like gag particles was completely suppressed or 
altered. This occurs because deletion or alteration of these functionally active res- 
idues at the DNA level affects every Pr55gag molecule. In contrast, when synthetic 
peptides are added to cells, which still contain functionally active HIV-gag-pre- 
cursor proteins due to the viral infection, peptides can only disturb but not block 
HIV assembly. Here, the effect may depend on the concentration of and the quan- 
titative relation between the synthetic peptides and the viral precursor proteins and, 
hence, the amount of HIV produced in individual cells. 
Recent, unpublished results further support our initial observations (S. Modrow 
et al., unpublished). It could be shown that the HIV-l-specific gag protein-derived 
peptides also inhibit the release of HIV-2 infectious particles and peptides derived 
from the respective gag-protein sequences of simian immunodeficiency virus (SIV; 
p l 8MA: FGLAESLLENKEGCQKILS; p27CA: GLGTNPTLEEMLTACQG) sig- 
nificantly reduced the release of SIV gag proteins from infected cells (Table 4). In 
particular, the investigated region of the capsid protein seems to be essential for 
particle formation. The amino acid sequences here are highly conserved among 
HIV, SIV and feline immunodeficiency virus and can neither be altered in the syn- 
thetic peptides without losing inhibitory activity nor in recombinant Pr55gag with- 
out losing the capacity to form virus-like particles (Fig. 5). These findings reflect 
the fact that the observed inhibitory effect of the synthetic peptides is not virus- 
340 351 
HIV-1 AATLEEMMTACQ 
331 342 
HIV-2/SIV NPTLEEMLTACQ 
337 348 
FIV ESTLEEKLRACQ 
Fig. 5. Sequence comparison of the assembly associated 
protein region present within the capsid protein part. Bold 
and underlined letters indicate the residues conserved 
between HIV-1, HIV-2, simian and feline immunodeficien- 
cy viruses (SIV and FIV). The identical residues were 
shown to be sensitive to alteration i  the HIV systems de- 
scribed in the text 
Table 4. Influence of SIV gag protein-derived peptides corresponding tothe regions active in 
inhibition of HIV-l-particle release on the release of SIV (strain J5) from infected cells measu- 
red by the quantification of SIV-gag-proteins p27 in capture assays after 6 days of incubation 
Peptide sequence SIV p27 capsid protein cell culture supernatants (ng/ml) 
(% inhibition in relation to p27 production of controls) 
FGLAESLLENKEGCQKLIS 1560 (84%) 
GLGTNPTLEEMLTACQG 1320 (86%) 
Virus control 9600 (0%) 
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type specific. These data indicate that inhibit ion of  virus assembly by synthetic 
peptides or derivatives thereof might open new perspectives for antiviral treatment 
by affecting lentivirus particle assembly. 
Conclusions and summary  
Using two different experimental  systems we were able to define two distinct re- 
gions in the sequence of gag proteins of HIV which function in the assembly of  
structural components of the virus and particle morphogenesis.  Since assembly 
could be inhibited by addit ion of synthetic non-toxic peptide compounds,  a new 
group of  antiviral agents may be developed. This approach represents a complete ly  
new inhibitory principle. Besides irreversibly blocking the synthesis of  progeny 
virus, this class of  pept idomimet ic  inhibitors might be of  special interest since non- 
infectious particles are released which should still be capable of  st imulating the 
immune system and helping to induce an improved immune status. Those effects 
have been observed when mice were vaccinated with Rauscher murine leukemia 
virus and treated s imultaneously with z idovudine and inter feron-a  [69]. 
Besides the development of antiviral compounds active viral protein regions ac- 
t ively involved in morphogenesis  may be developed for appl icat ions in gene ther- 
apy using assembly defective gag proteins to negatively inf luence virus produc- 
tion via transdominant-negat ive eff cts. 
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